Primary study · included by 1 review

Diagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELISA on bullous pemphigoid.

Li 2022 · Li Suo, Xiang Ruiyu, Jing Ke, et al. · Chinese medical journal · 2022

Included by

Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

Non-Cochrane · DTA · 2026 · cited as Li 2022 · Table 2; References

Outcome this study informs	Pooled effect	Evidence	Certainty
Diagnostic agreement between ELISA and DIF (risk difference in test positivity) ELISA (BP180 and/or BP230) in bullous pemphigoid (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy	RD 0.19 [0.13, 0.25]	27 studies · 2238 participants	GRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity) ELISA for BP180 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy	RD 0.26 [0.19, 0.33]	35 studies · 2776 participants	GRADE not reported

1 including review in total.